166 related articles for article (PubMed ID: 19944966)
1. Immunostimulants for malignant gliomas.
Butowski N
Neurosurg Clin N Am; 2010 Jan; 21(1):53-65. PubMed ID: 19944966
[TBL] [Abstract][Full Text] [Related]
2. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.
Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
Neuro Oncol; 2016 Aug; 18(8):1157-68. PubMed ID: 26984745
[TBL] [Abstract][Full Text] [Related]
3. Interferons and interferon inducers in cancer treatment.
Krown SE
Semin Oncol; 1986 Jun; 13(2):207-17. PubMed ID: 2424089
[No Abstract] [Full Text] [Related]
4. [Antitumor effect of Corynebacterium parvum and poly ICLC on experimental brain tumors].
Kiya K; Kitaoka T; Okamoto H; Harada K; Uozumi T; Toge T; Hattori T; Machida H
Neurol Med Chir (Tokyo); 1983 Nov; 23(11):841-8. PubMed ID: 6201759
[No Abstract] [Full Text] [Related]
5. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
[TBL] [Abstract][Full Text] [Related]
6. Brain tumor immunotherapy with type-1 polarizing strategies.
Okada H
Ann N Y Acad Sci; 2009 Sep; 1174():18-23. PubMed ID: 19769732
[TBL] [Abstract][Full Text] [Related]
7. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy.
Cao Y; Tsien CI; Shen Z; Tatro DS; Ten Haken R; Kessler ML; Chenevert TL; Lawrence TS
J Clin Oncol; 2005 Jun; 23(18):4127-36. PubMed ID: 15961760
[TBL] [Abstract][Full Text] [Related]
8. Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.
Talmadge JE; Chirigos MA
Springer Semin Immunopathol; 1985; 8(4):429-43. PubMed ID: 3879016
[No Abstract] [Full Text] [Related]
9. Immunotherapeutic potential in murine tumor models of polyinosinic-polycytidylic acid and poly-L-lysine solubilized by carboxymethylcellulose.
Talmadge JE; Adams J; Phillips H; Collins M; Lenz B; Schneider M; Chirigos M
Cancer Res; 1985 Mar; 45(3):1066-72. PubMed ID: 3971361
[TBL] [Abstract][Full Text] [Related]
10. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
Butowski N; Lamborn KR; Lee BL; Prados MD; Cloughesy T; DeAngelis LM; Abrey L; Fink K; Lieberman F; Mehta M; Ian Robins H; Junck L; Salazar AM; Chang SM
J Neurooncol; 2009 Jan; 91(2):183-9. PubMed ID: 18850068
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II trials of poly(ICLC) in malignant brain tumor patients.
Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
J Interferon Res; 1982; 2(1):1-4. PubMed ID: 6180095
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.
Dillon PM; Petroni GR; Smolkin ME; Brenin DR; Chianese-Bullock KA; Smith KT; Olson WC; Fanous IS; Nail CJ; Brenin CM; Hall EH; Slingluff CL
J Immunother Cancer; 2017 Nov; 5(1):92. PubMed ID: 29157306
[TBL] [Abstract][Full Text] [Related]
13. A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy.
De Waele J; Verhezen T; van der Heijden S; Berneman ZN; Peeters M; Lardon F; Wouters A; Smits ELJM
J Exp Clin Cancer Res; 2021 Jun; 40(1):213. PubMed ID: 34172082
[TBL] [Abstract][Full Text] [Related]
14. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809
[TBL] [Abstract][Full Text] [Related]
15. Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys.
Puri SK; Dutta GP; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1996 Jan; 16(1):49-52. PubMed ID: 8640451
[TBL] [Abstract][Full Text] [Related]
16. Immunochemotherapy for Leishmania donovani infection in golden hamsters: combinatorial action of poly ICLC plus L-arginine and sodium stibogluconate (Stibanate).
Bhakuni V; Kulkarni S; Ali V; Singh UK; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1999 Oct; 19(10):1103-6. PubMed ID: 10547149
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic applications of cytokines for immunostimulation and immunosuppression: an update.
Cardi G; Ciardelli TL; Ernstoff MS
Prog Drug Res; 1996; 47():211-50. PubMed ID: 8961768
[No Abstract] [Full Text] [Related]
18. Double-Stranded RNA Immunomodulators in Prostate Cancer.
Salazar AM; Celis E
Urol Clin North Am; 2020 Nov; 47(4S):e1-e8. PubMed ID: 33446322
[TBL] [Abstract][Full Text] [Related]
19. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs.
Ammi R; De Waele J; Willemen Y; Van Brussel I; Schrijvers DM; Lion E; Smits EL
Pharmacol Ther; 2015 Feb; 146():120-31. PubMed ID: 25281915
[TBL] [Abstract][Full Text] [Related]
20. [Effect of interferon inducer (poly ICLC) in the treatment of malignant brain tumor (author's transl)].
Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
No To Shinkei; 1982 Mar; 34(3):267-73. PubMed ID: 7093065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
